2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

Feldman, Ted; Hirshfeld, John W.; Kern, Morton J.; King, Spencer B.; Morrison, Douglass A.; O’Neill, William W.; Schaff, Hartzell V.; Whitlow, Patrick L.; Williams, David O.; Smith, Sidney C.; Jacobs, Alice K.; Adams, Cynthia D.; Anderson, Jeffrey L.; Buller, Christopher E.; Creager, Mark A.; Ettinger, Steven M.; Halperin, Jonathan L.; Hunt, Sharon A.; Krumholz, Harlan M.; Kushner, Frederick G.; Lytle, Bruce W.; Nishimura, Rick A.; Page, Richard L.; Riegel, Bárbara; Tarkington, Lynn G.; Yancy, Clyde W.

doi:10.1161/circulationaha.107.188208

Cited by 703 publications

(183 citation statements)

References 181 publications

(119 reference statements)

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…Hydration also reduces the direct toxic effects of the contrast agent on the kidney by diluting and decreasing its viscosity in the renal tubules [8,9]. A meta-analysis of six trials demonstrated that oral hydration with a pre-specified expansion volume is as effective as intravenous for the prevention of contrast-induced nephropathy.…”

Section: Discussionmentioning

confidence: 99%

Implications of Renal Complications In Out Patient Referral for Coronary Angiography: Prospective Observational Study of 98 Cases

Js¹,

Payot²,

Zabalawi³

et al. 2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

The incidence of acute kidney failure remains high, due to the multiplication of interventional procedures on subjects at risk. It increases both morbi-mortality in hospitals and in the long term. The identification of patients atriskis primordial in order to implement the preventiv emeasures, whose expansion remains the 'gold standard'. The realization of a coronary angiography in ambulatory care in this type of patient at risk is possible without increasing renal morbidity, under the cover of a good hydration.Introduction: Acute renal failure is a complication that remains common after injection of contrast agent. It increases both morbidity and hospital mortality in the long term. We wanted to carry out a prospective observational study to evaluate the incidence of renal complications (acute renal failure, dialysis) of patients referred as an outpatient in our center for coronary angiography and who have benefited from measures of prevention of renal toxicity as recommended by learned societies. Methodology:We conducted a prospective study at the Yves Le Foll hospital in Saint Brieuc over a period of 4 months from November 2015 to February 2016, in patients admitted on an outpatient basis for coronary angiography who had previously suspended all drugs with nephrotoxic potential and with hydration surrounding the examination. A survey card was developed to collect, after informed consent, sociodemographic data, risk factors, comorbidities, clinical and paraclinical data. All data was entered and analyzed using SPSS software version 18.0.Results: Ninety-eight patients had an ambulatory coronary angiogram during this period. The sex ratio was 3.66 in favor of the male genus with an average age of 65 years. Three-quarters of the population (71%) had at least one risk factor for contrast-induced nephropathy. The mean clearance values before and after coronary angiography were almost similar (80 μmol/l) without significant variation. No impairment of renal function was observed in patients at risk regardless of the amount of contrast injected (range: between 30 and 277 ml). When patients accumulate risk factors for induced nephropathy in the contrast medium, there is an increase in the blood creatinine level with the number of factors but no significant change (p: 0.24) of renal function after iodine injection. Conclusion:The incidence of acute kidney injury remains high, due to the increase of intervention procedures in subjects at risk. The identification of these patients at risk is paramount in order to implement the preventive measures of which volume expansion remains the gold standard. The realization of an outpatient coronary angiography in this type of patient at risk is feasible without increasing renal morbidity with a good hydration.

show abstract

Section: Discussionmentioning

confidence: 99%

Implications of Renal Complications In Out Patient Referral for Coronary Angiography: Prospective Observational Study of 98 Cases

Js¹,

Payot²,

Zabalawi³

et al. 2017

J Clin Exp Cardiolog

View full text Add to dashboard Cite

show abstract

“…Previous studies 34 -37 have reported that the cytochrome P450 2C19 polymorphism, diabetes mellitus, sex, smoking status, and renal insufficiency were significant predictors of P2Y 12 inhibition after clopidogrel administration. 18 An association of a history of CHD with the response to clopidogrel has not been demonstrated. Randomization is a method based on chance alone by which study participants are assigned to different trial arms.…”

Section: Discussionmentioning

confidence: 99%

“…18 Patients who concomitantly used anticoagulant agents were also excluded. Patients who had hypersensitivity to aspirin or clopidogrel, a serious bleeding tendency, a history of intracranial hemorrhage, signs of active bleeding, or uncontrolled hypertension were not included.…”

Section: Inclusion and Exclusion Criteriamentioning

confidence: 99%

Comparison of Antiplatelet Effect and Tolerability of Clopidogrel Resinate With Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD-Equivalent Risks: A Phase IV, Prospective, Double-Dummy, Parallel-Group, 4-Week Noninferiority Trial

Suh

Seung

Gwak

et al. 2011

Clinical Therapeutics

View full text Add to dashboard Cite

“…Subsequent studies extend on the indications for its use in the setting of acute coronary syndromes (ACS) [2], ST-segment elevation myocardial infarction [3,4] and percutaneous coronary intervention (PCI) [5,6]. Despite the robust clinical findings and indications for clopidogrel usage derived from these large-scale clinical trials performed over the course of the past decade, which are clearly reflected in clinical practice guidelines [7][8][9], there are a large number of uncertainties regarding clopidogrel usage in daily real world practice. This is reflected by the plethora of publications dealing with clopidogrel over the course of the past several years.…”

mentioning

confidence: 99%

“…Other studies have confirmed these findings that are in line with the more rapid and potent effects of this dosing regimen, and which now represents the loading dose of choice by most interventionalists. Importantly, the updated PCI guidelines have recently provided a class I indication for a 600 mg dosing regimen, even though the data to support this are limited to relatively small samplesized studies [9]. It is for this reason that a 600 mg clopidogrel dose is not approved by regulatory authorities.…”

mentioning

confidence: 99%

Contemporary issues on clopidogrel therapy: a critical appraisal

Capodanno

Angiolillo

2009

Intern Emerg Med

View full text Add to dashboard Cite

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

Cited by 703 publications

References 181 publications

Implications of Renal Complications In Out Patient Referral for Coronary Angiography: Prospective Observational Study of 98 Cases

Implications of Renal Complications In Out Patient Referral for Coronary Angiography: Prospective Observational Study of 98 Cases

Comparison of Antiplatelet Effect and Tolerability of Clopidogrel Resinate With Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD-Equivalent Risks: A Phase IV, Prospective, Double-Dummy, Parallel-Group, 4-Week Noninferiority Trial

Contemporary issues on clopidogrel therapy: a critical appraisal

Contact Info

Product

Resources

About